<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269304</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS - 256931</org_study_id>
    <secondary_id>47270</secondary_id>
    <secondary_id>210572/Z/18/Z</secondary_id>
    <nct_id>NCT04269304</nct_id>
  </id_info>
  <brief_title>Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE</brief_title>
  <acronym>PINNACLE</acronym>
  <official_title>Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a prospective non-interventional study including 400 early AMD patients (=600
      untreated early AMD eyes, including both unilateral (AREDS IV) and bilateral (≥AREDS II))
      over 3 years to specifically investigate the morphological sequence of events preceding the
      conversion towards late AMD. All patients will be followed by OCT imaging every 4 months to
      detect the earliest focal sites of disease progression. As soon as focal areas of change are
      observed by the VRC, a targeted follow-up schedule will be triggered to investigate the
      events at that area of change in a targeted manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit patients with 1) intermediate AMD in one eye and advanced AMD in the
      non-study eye or 2) patients with bilateral intermediate AMD (where both eyes will be
      included). As some participants are symptomless at the stage of intermediate AMD, we will
      recruit from hospital databases including imaging databases and ophthalmology and optometry
      practices and engagement with Patient Societies e.g. the Macular Society and patient public
      involvement meetings.

      There will be four clinical sites performing detailed assessments on 50 patients each and, to
      increase sample size, an additional eight referral sites in the UK who will each enrol and
      follow 25 study patients by SD-OCT every 4 months. The acquired images from these referral
      sites will be sent to the Vienna Reading Centre for morphological identification of focal
      events. If a focal event is detected, participants will then be referred for a detailed,
      targeted assessment at either the University of Southampton or Moorfields Eye Hospital as
      detailed below.

      After consent, patients will undergo visual function tests (ETDRS visual acuity,
      microperimetry) and multimodal imaging including fundus photographs, OCT scans, OCT
      angiography, autofluorescence and adaptive optics imaging. The visual function tests will be
      repeated annually and the multimodal imaging will be done at 4 monthly intervals for 3 years.
      Blood will be taken at the first visit for DNA analysis.

      200 patients (main cohort) will undergo dense retinal phenotyping at 10 visits. Medical and
      smoking history, genotype and body mass index will also be included in the analysis as has
      been done previously. As well as structural tests, functional tests will be performed at
      baseline and end of the study using both microperimetry (a type of visual field test to
      create a &quot;retinal sensitivity map&quot; of the quantity of light perceived in specific parts of
      the retina) to identify focal changes and low luminance visual acuity to assess global
      changes. To increase sample size but make the study feasible an additional 200 patients at UK
      referral sites will undergo 4 monthly OCT and be referred to Southampton / Moorfields for
      dense phenotyping only if a focal event is detected by OCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity / specificity of OCT and autofluorescence parameters.</measure>
    <time_frame>3 years</time_frame>
    <description>Identified by machine learning (ML) at predicting disease progression defined as focal conversion towards advanced AMD e.g. change in drusen volume, development of new geographic atrophy / choroidal neovascularisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity / specificity of novel imaging characteristics</measure>
    <time_frame>3 years</time_frame>
    <description>For example, AO-OCT, OCT-A, at predicting disease progression; ROC curves; time from development of imaging change to development of these end-points; structure-function correlation; structure-genotype correlation; predictive risk models.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>Intermediate Age-Related Macular Degeneration Patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA for genotype analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with 1) intermediate AMD in one eye and advanced AMD in the non-study eye or 2)
        patients with bilateral intermediate AMD (where both eyes will be included).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ≥ 55 years with either intermediate AMD (as defined by Ferris et al PMID:
             23332590) in both eyes, i.e. large drusen &gt; 125 um and/or any definite hyper- or
             hypopigmentary abnormalities associated with medium or large drusen; or intermediate
             AMD as defined above in one eye (study eye) and advanced AMD (geographic atrophy or
             choroidal neovascularization secondary to AMD) in the other eye.

          -  Subjects should have media clarity and pupillary dilation for adequate imaging and
             functional tests.

        Exclusion Criteria:

          -  Co-existent ocular disease, which might affect visual function or retinal morphology

          -  Established glaucoma in either study eye or fellow eye with evidence of visual field
             loss or retinal nerve fibre loss (ocular hypertension is not an exclusion criterion
             unless associated with visual field loss or retinal nerve fibre loss in either eye).

          -  Cataract sufficient to affect retinal imaging

          -  Myopia &gt; minus 6 diopters or a history of myopia &gt; minus 6 diopters if patient has had
             cataract / refractive surgery.

          -  Major ocular surgery 3 months prior or anticipated within the next 6 months following
             enrolment.

          -  Taking drugs known to cause retinal toxicity such as hydroxychloroquine or tamoxifen

          -  OCT evidence of geographic atrophy (or complete RPE and outer retinal atrophy (cRORA).
             This is (1) a region of hypertransmission of at least 250 mm in diameter, (2) a zone
             of attenuation or disruption of the RPE of at least 250 mm in diameter, (3) evidence
             of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other
             signs of an RPE tear.

          -  OCT evidence of choroidal neovascularization e.g sub-retinal scar tissue, sub-retinal
             fluid or intra-retinal fluid associated with a pigment epithelial detachment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Lotery, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southampton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Lotery, Prof</last_name>
    <phone>023 8120 5049</phone>
    <phone_ext>5049</phone_ext>
    <email>A.J.Lotery@soton.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PINNACLE email address Sutton/Wilson, BSc</last_name>
    <phone>023 8120 5240</phone>
    <phone_ext>5240</phone_ext>
    <email>pinnacle@soton.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Riedl</last_name>
      <phone>+43 (0)1 40400 79240</phone>
      <email>sophie.riedl@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ursula Schmidt-Erfurth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghislaine L Traber, MD</last_name>
      <phone>+41 (0) 61 265 78 88</phone>
      <email>ghislaine.traber@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Hauenstein</last_name>
      <phone>+41 61 265 87 18</phone>
      <email>Daniela.Hauenstein@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Hendrik Scholl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Princess Alexandra Hospital Nhs Foundation Trust</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naima Barbar</last_name>
      <email>n.babar@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Priya Prakash, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals Nhs Trust</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Gedge</last_name>
      <email>Ian.Gedge@porthosp.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adam Booth, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrin Watkins, Ms</last_name>
      <phone>023 8120 4606</phone>
      <phone_ext>4606</phone_ext>
      <email>Catrin.Watkins@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Magdalena Ansari, Ms</last_name>
      <phone>023 8120 4606</phone>
      <phone_ext>4606</phone_ext>
      <email>Magdalena.Ansari@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew J Lotery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frimley Health Nhs Foundation Trust</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clare Denford</last_name>
      <phone>01276 522522</phone>
      <phone_ext>2522</phone_ext>
      <email>clare.denford@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Geeta Menon, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salisbury Nhs Foundation Trust</name>
      <address>
        <city>Salisbury</city>
        <state>Wiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Bell</last_name>
      <phone>01722 425026</phone>
      <phone_ext>2026</phone_ext>
      <email>lbell1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rashi Arora, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol Nhs Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eleanor Hiscott</last_name>
      <email>Eleanor.Hiscott@UHBristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Clare Bailey, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayse Barnes, Ms</last_name>
      <phone>0207 566 2109</phone>
      <email>ayse.barnes1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sobha Sivaprasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London Nhs Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie Preston</last_name>
      <phone>07867 780838</phone>
      <email>anne-marie.preston@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Martin Harris, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy'S and St Thomas' Nhs Ft</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Armoogum</last_name>
      <phone>020 7188 7188</phone>
      <phone_ext>51199</phone_ext>
      <email>Christina.Armoogum@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Samantha Mann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Public-and-patients/Opt-out-of-research.aspx</url>
    <description>Research opt out process for PINNACLE</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information can be made available on application to the Trial Management Group.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

